Oligonucleotide modulation of multidrug resistance-associated protein
AssigneeIsis Pharmaceuticals, Inc.
InventorsEdgardo Baracchini, Jr., Clarence F. Bennett
Life of this patent
Estimating the term…
Loading patent…
AssigneeIsis Pharmaceuticals, Inc.
InventorsEdgardo Baracchini, Jr., Clarence F. Bennett
Estimating the term…
Compositions and methods are provided for the treatment and diagnosis of diseases or conditions amenable to treatment through modulation of the synthesis or metabolism of multidrug resistance-associated protein (MRP). In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with nucleic acids encoding multidrug resistance-associated protein (MRP). Methods of treating animals suffering from diseases or conditions amenable to therapeutic intervention by modulating multidrug resistance with an oligonucleotides specifically hybridizable with RNA or DNA corresponding to multidrug resistance-associated protein (MRP) are disclosed. Methods of preventing the development of multidrug resistance and of improving the efficacy of chemotherapy are also-disclosed.
An oligonucleotide selected from the group consisting of SEQ ID NO:
A method of inhibiting the synthesis of multidrug resistance-associated protein in a cultured cell or tissue comprising contacting the cell or tissue with an isolated oligonucleotide selected from the group consisting of SEQ ID NO:
Dependencies are inferred from the claim text.